Q-omics provides the consensus-scored ADSS1 profile across patient tissues and cancer cell-line models. ADSS1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ADSS1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ADSS1 protein abundance shows 18,258 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UVM, KIRC, and HNSC as cancer lineages where ADSS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADSS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADSS1 survival associations across molecular data types. ADSS1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADSS1 RNA expression–survival associations across cancer types. High ADSS1 expression shows unfavorable associations in UVM, LUAD, COAD, LGG and CHOL, but favorable associations in OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ADSS1 RNA expression.
This table summarizes ADSS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ADSS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADSS1 shows lower tumor expression in KIRP, BRCA and KICH and higher tumor expression in KIRC, LUAD and LUSC. The KIRC box plot shows higher ADSS1 RNA expression in tumor versus normal tissue (log2 FC = +2.318, t-test p < 0.001).
This table shows molecular features associated with ADSS1 in patient tissues and cancer cell lines. In patient samples, ADSS1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADSS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
